Exploring Control in Contraceptive Use: Perspectives on IUD Self-Removal
As a nonprofit pharmaceutical organization specializing in women’s health, Medicines360 works to democratize access to medicines and health care products for women. We are guided by our values – one of which is to support health equity for women regardless of geographic location or economic status.[1] We developed and brought our anchor product to market […]
FDA Approves Medicines360’s Supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg as Treatment of Heavy Menstrual Bleeding
New Indication Expected to Increase Treatment Options of Heavy Menstrual Bleeding for up to five years in patients who choose intrauterine contraception as their method of contraception July 10, 2023 SAN FRANCISCO, CA– Medicines360, a global nonprofit organization with a mission to catalyze equitable access to quality medicines for women, announced today that the U.S. […]
Medicines360 Appoints Andrea Olariu, MD, PhD as Chief Executive Officer
Dr. Olariu brings depth of expertise in Clinical, Medical and Regulatory Affairs, and Product Development SAN FRANCISCO – May [30] – Medicines360, a mission-driven nonprofit women’s health pharmaceutical organization, announced today that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately. Dr. Olariu served most recently as Chief […]
More Bumps in Reproductive Healthcare Access
At M360, we believe that all women should have control over their reproductive healthcare, including abortion and contraception. Since the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization in June of last year, the reproductive health policy landscape has changed profoundly. Women today face drastic new barriers to accessing the full range of […]
Reduced Drug Pricing Within View and More Good Policy News
At Medicines360, our work is focused on addressing gaps women face in accessing the medicines they need. While that means we pursue drug research and development, as a mission-driven organization, it also demands that we pay attention to and speak up about policies that negatively impact the health and well-being of women we serve. In […]
Supreme Court’s Decision in Mifepristone Case Protects Women and Science, For Now
San Francisco, CA – Last week, the United States Supreme Court granted a stay of execution, requested by the Department of Justice (DOJ) and Danco Laboratories, in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al. This stay allows mifepristone – one of two drugs used in medication abortion – […]
Medicines360 Stands with Women in Wake of Texas Mifepristone Case
San Francisco, CA – Today, following the recent federal court decision in Texas designed to pull Mifepristone from the U.S. market, Medicines360 CEO Tina Raine-Bennett, MD, MPH, released the following statement: “Last week, a lone federal judge in Texas declared in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al […]
2021-2022 Daniel R. Mishell, Jr, MD Outstanding Article Award Presented to Tina Raine-Bennett, MD, MPH, FACOG
Medicines360 Chief Executive Officer, Tina Raine-Bennett, MD, MPH, FACOG, was recently awarded the 2021-2022 Daniel R. Mishell, Jr, MD Outstanding Article Award for her original research article entitled, “Ectopic pregnancy prevention: Further evidence of benefits of prescription contraceptives.” Dr. Raine-Bennett’s study explored the incidence of ectopic pregnancy in the last decade in U.S. women who […]
Looking Back at 2022 & Moving Forward into 2023
Dear Friends of Medicines360 – Happy New Year! 2023 is already off to a roaring start and Medicines360 is excited to share the inaugural edition of “All Access,” our newly launched bulletin. With drug prices in the U.S. continuing to rise, breakthrough products and essential medications have become even more unaffordable, particularly for people without health insurance. As […]
Victories and Reflections on Medicines360 Policy Work in 2022
Nearly three years into the pandemic, it is impossible to ignore that the health care policy environment has been forever changed — and that change continues. The pandemic laid bare long-standing inequities in access for people of color, people with low incomes, LGBTQ+ people, women, and people who live at the intersections of these identities. […]
